Zealand Pharma Stock News

Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

Zealand Pharma A/S (NASDAQ:ZEAL)s stock price rose 5.5% during trading on Wednesday . The stock traded as high as $21.88 and last traded at $21.88. Approximately 228 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 16,498 shares. The stock had previously closed at $20.73. Separately, Zacks Investment []

Zealand Pharma A/S (NASDAQ:ZEAL)s stock price gapped up prior to trading on Friday . The stock had previously closed at $21.30, but opened at $22.00. Zealand Pharma A/S shares last traded at $22.00, with a volume of 9 shares changing hands. Separately, Zacks Investment Research upgraded shares of Zealand Pharma A/S from a sell rating [] The post Zealand Pharma A/S (NASDAQ:ZEAL) Shares Gap Up to $21.30 appeared first on ETF Daily News .

Shares of Zealand Pharma A/S (NASDAQ:ZEAL) gapped down before the market opened on Monday . The stock had previously closed at $23.15, but opened at $22.07. Zealand Pharma A/S shares last traded at $22.07, with a volume of 100 shares traded. Separately, Zacks Investment Research raised Zealand Pharma A/S from a sell rating to a []

Zealand Pharma A/S (NASDAQ:ZEAL) reached a new 52-week low during trading on Friday . The stock traded as low as $22.33 and last traded at $23.15, with a volume of 1600 shares. The stock had previously closed at $23.09. Separately, Zacks Investment Research raised Zealand Pharma A/S from a sell rating to a hold rating []

Zealand Pharma A/S (NASDAQ:ZEAL) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, []

Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q3 2021 Results - Earnings Call Transcript

Company announcement – No. 64  / 202 1

Company announcement – No. 61 / 2021

Company announcement – No. 60  / 20 2 1

C ompany a nnouncement – No. 59 / 202 1

Company announcement – No. 58 / 2021

C ompany a nnouncement – No. 57 / 202 1

Company announcement – No. 56 / 20 2 1

Company announcement - No. 56 / 2021